{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T06:30:42Z","timestamp":1781850642866,"version":"3.54.5"},"reference-count":23,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Vet Emergen Crit Care"],"published-print":{"date-parts":[[2024,1]]},"abstract":"Abstract<\/jats:title>Objective<\/jats:title>To assess the ability of intranasal atipamezole to reverse sedative effects of xylazine in dogs.<\/jats:p><\/jats:sec>Design<\/jats:title>Prospective proof\u2010of\u2010concept study.<\/jats:p><\/jats:sec>Setting<\/jats:title>University research laboratory.<\/jats:p><\/jats:sec>Animal<\/jats:title>Six healthy, staff\u2010owned dogs.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Dogs were sedated with 1.1\u00a0mg\/kg of xylazine intravenously. The sedation score of each dog was recorded every 5\u00a0minutes until they achieved a sedation score of >13\/21 for 3 readings. Once achieved, 0.3\u00a0mg\/kg of atipamezole was administered intranasally using a mucosal atomization device. Sedation scores continued to be recorded every 5\u00a0minutes until successful reversal was achieved (<4\/21).<\/jats:p><\/jats:sec>Measurements and Main Results<\/jats:title>Average times to standing and normal wakefulness after administration of intranasal atipamezole were 6\u00a0minutes, 30\u00a0seconds and 7\u00a0minutes, 20\u00a0seconds, respectively.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Intranasal atipamezole successfully reversed the sedation effects of xylazine. The findings of this study provide justification for future controlled prospective studies into the potential use of intranasal atipamezole in a variety of settings including exposure to xylazine in operational canines as well as bioavailability studies for optimal dosing.<\/jats:p><\/jats:sec>","DOI":"10.1111\/vec.13357","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T02:19:55Z","timestamp":1701915595000},"page":"57-62","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of the use of intranasal atipamezole to reverse the sedative effects of xylazine in dogs"],"prefix":"10.1111","volume":"34","author":[{"given":"Alex P.","family":"Focken","sequence":"first","affiliation":[{"name":"Department of Small Animal Clinical Sciences, Western College of Veterinary Medicine University of Saskatchewan Saskatoon Saskatchewan Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9951-7151","authenticated-orcid":false,"given":"Jordan M.","family":"Woodsworth","sequence":"additional","affiliation":[{"name":"Department of Small Animal Clinical Sciences, Western College of Veterinary Medicine University of Saskatchewan Saskatoon Saskatchewan Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Loewen","sequence":"additional","affiliation":[{"name":"Department of Small Animal Clinical Sciences, Western College of Veterinary Medicine University of Saskatchewan Saskatoon Saskatchewan Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11524-011-9662-6"},{"key":"e_1_2_11_3_1","unstructured":"PayerDE YoungMM Maloney\u2010HallB et\u00a0al.Adulterants contaminants and co\u2010occurring substances in drugs on the illegal market in Canada: an analysis of data from drug seizures drug checking and urine toxicology.Canadian Centre on Substance Use and Addiction;2020."},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-017-1027-2"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109380"},{"key":"e_1_2_11_6_1","unstructured":"AntonJ.\u2018Fatal combination\u2019: Animal tranquilizer xylazine linked to 4 Sask. deaths.CBC News. March 4 2021."},{"key":"e_1_2_11_7_1","unstructured":"ReinbergS.Animal sedative is driving rise in fatal drug ODs. HealthDay. Accessed July 12 2022.https:\/\/consumer.healthday.com\/9\u201020\u2010an\u2010animal\u2010sedative\u2010is\u2010driving\u2010rise\u2010in\u2010fatal\u2010drug\u2010ods\u20102655046140.html"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cvsm.2021.04.011"},{"issue":"11","key":"e_1_2_11_9_1","first-page":"885","article-title":"A review of the physiological effects of alpha2\u2010agonists related to the clinical use of medetomidine in small animal practice","volume":"44","author":"Sinclair MD","year":"2003","journal-title":"Can Vet J"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563658108990293"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006565-200112000-00012"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119421375.ch10"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.55460\/6XRM-EW4X"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.14734"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-2995.2005.00244.x"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.17221\/74\/2017-VETMED"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.5818\/1529-9651-22.3.91"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/vaa.12187"},{"issue":"5","key":"e_1_2_11_19_1","first-page":"501","article-title":"Intranasal naltrexone and atipamezole for reversal of white\u2010tailed deer immobilized with carfentanil and medetomidine","volume":"51","author":"Shury TK","year":"2010","journal-title":"Can Vet J"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.128.14.323"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep31732"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.2174\/187221108783331429"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2007.03.025"},{"key":"e_1_2_11_24_1","unstructured":"National Center for Biotechnology Information.PubChem Compound Summary for CID 71310 Atipamezole."}],"container-title":["Journal of Veterinary Emergency and Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vec.13357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T07:24:34Z","timestamp":1706685874000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vec.13357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1111\/vec.13357"],"URL":"https:\/\/doi.org\/10.1111\/vec.13357","archive":["Portico"],"relation":{},"ISSN":["1479-3261","1476-4431"],"issn-type":[{"value":"1479-3261","type":"print"},{"value":"1476-4431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,6]]},"assertion":[{"value":"2023-01-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}